AustralieFrV1, PubMed, Curation, bibRecord, 001F62

Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial.

Identifieur interne : 001F62 ( PubMed/Curation ); précédent : 001F61; suivant : 001F63

Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial.

Auteurs : Michelle L. O'Donoghue [États-Unis] ; Ruchira Glaser [États-Unis] ; Matthew A. Cavender [États-Unis] ; Philip E. Aylward [Australie] ; Marc P. Bonaca [États-Unis] ; Andrzej Budaj [Pologne] ; Richard Y. Davies [États-Unis] ; Mikael Dellborg [Suède] ; Keith A A. Fox [Royaume-Uni] ; Jorge Antonio T. Gutierrez [États-Unis] ; Christian Hamm [Allemagne] ; Robert G. Kiss [Hongrie] ; František Kovar ; Julia F. Kuder [États-Unis] ; Kyung Ah Im [États-Unis] ; John J. Lepore [États-Unis] ; Jose L. Lopez-Sendon [Espagne] ; Ton Oude Ophuis [Pays-Bas] ; Alexandr Parkhomenko [Ukraine] ; Jennifer B. Shannon [États-Unis] ; Jindrich Spinar [République tchèque] ; Jean-Francois Tanguay [Canada] ; Mikhail Ruda [Russie] ; P Gabriel Steg [France] ; Pierre Theroux [Canada] ; Stephen D. Wiviott [États-Unis] ; Ian Laws [États-Unis] ; Marc S. Sabatine [États-Unis] ; David A. Morrow [États-Unis]

Source :

JAMA [ 1538-3598 ] ; 2016.

RBID : pubmed:27043082

Descripteurs français

KwdFr :
- Adulte d'âge moyen, Algorithmes, Calendrier d'administration des médicaments, Cyclopropanes (effets indésirables), Cyclopropanes (usage thérapeutique), Femelle, Hospitalisation, Humains, Infarctus du myocarde (enzymologie), Infarctus du myocarde (mortalité), Infarctus du myocarde (traitement médicamenteux), Inhibiteurs de protéines kinases (effets indésirables), Inhibiteurs de protéines kinases (usage thérapeutique), Ischémie myocardique (), Mâle, Méthode en double aveugle, Protéine C-réactive (analyse), Prévention secondaire, Pyridines (effets indésirables), Pyridines (usage thérapeutique), Revascularisation myocardique, Récidive, Sujet âgé, p38 Mitogen-Activated Protein Kinases (antagonistes et inhibiteurs), Échec thérapeutique.
MESH :
- analyse : Protéine C-réactive.
- antagonistes et inhibiteurs : p38 Mitogen-Activated Protein Kinases.
- effets indésirables : Cyclopropanes, Inhibiteurs de protéines kinases, Pyridines.
- enzymologie : Infarctus du myocarde.
- mortalité : Infarctus du myocarde.
- traitement médicamenteux : Infarctus du myocarde.
- usage thérapeutique : Cyclopropanes, Inhibiteurs de protéines kinases, Pyridines.
- Adulte d'âge moyen, Algorithmes, Calendrier d'administration des médicaments, Femelle, Hospitalisation, Humains, Ischémie myocardique, Mâle, Méthode en double aveugle, Prévention secondaire, Revascularisation myocardique, Récidive, Sujet âgé, Échec thérapeutique.

English descriptors

KwdEn :
- Aged, Algorithms, C-Reactive Protein (analysis), Cyclopropanes (adverse effects), Cyclopropanes (therapeutic use), Double-Blind Method, Drug Administration Schedule, Female, Hospitalization, Humans, Male, Middle Aged, Myocardial Infarction (drug therapy), Myocardial Infarction (enzymology), Myocardial Infarction (mortality), Myocardial Ischemia (prevention & control), Myocardial Ischemia (surgery), Myocardial Revascularization, Protein Kinase Inhibitors (adverse effects), Protein Kinase Inhibitors (therapeutic use), Pyridines (adverse effects), Pyridines (therapeutic use), Recurrence, Secondary Prevention, Treatment Failure, p38 Mitogen-Activated Protein Kinases (antagonists & inhibitors).
MESH :
- chemical , adverse effects : Cyclopropanes, Protein Kinase Inhibitors, Pyridines.
- chemical , analysis : C-Reactive Protein.
- chemical , antagonists & inhibitors : p38 Mitogen-Activated Protein Kinases.
- chemical , therapeutic use : Cyclopropanes, Protein Kinase Inhibitors, Pyridines.
- drug therapy : Myocardial Infarction.
- enzymology : Myocardial Infarction.
- mortality : Myocardial Infarction.
- prevention & control : Myocardial Ischemia.
- surgery : Myocardial Ischemia.
- Aged, Algorithms, Double-Blind Method, Drug Administration Schedule, Female, Hospitalization, Humans, Male, Middle Aged, Myocardial Revascularization, Recurrence, Secondary Prevention, Treatment Failure.

Abstract

p38 Mitogen-activated protein kinase (MAPK)-stimulated inflammation is implicated in atherogenesis, plaque destabilization, and maladaptive processes in myocardial infarction (MI). Pilot data in a phase 2 trial in non-ST elevation MI indicated that the p38 MAPK inhibitor losmapimod attenuates inflammation and may improve outcomes.

DOI: 10.1001/jama.2016.3609
PubMed: 27043082

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001F87

Links to Exploration step

pubmed:27043082

Curation

No country items

František Kovar

<affiliation><nlm:affiliation>Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic.</nlm:affiliation>
<wicri:noCountry code="subField">Slovak Republic</wicri:noCountry>
</affiliation>

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial.</title>
<author><name sortKey="O Donoghue, Michelle L" sort="O Donoghue, Michelle L" uniqKey="O Donoghue M" first="Michelle L" last="O'Donoghue">Michelle L. O'Donoghue</name>
<affiliation wicri:level="2"><nlm:affiliation>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Glaser, Ruchira" sort="Glaser, Ruchira" uniqKey="Glaser R" first="Ruchira" last="Glaser">Ruchira Glaser</name>
<affiliation wicri:level="2"><nlm:affiliation>Metabolic Pathways and Cardiovascular Unit, Research and Development, GlaxoSmithKline, Collegeville, Pennsylvania.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Metabolic Pathways and Cardiovascular Unit, Research and Development, GlaxoSmithKline, Collegeville</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Cavender, Matthew A" sort="Cavender, Matthew A" uniqKey="Cavender M" first="Matthew A" last="Cavender">Matthew A. Cavender</name>
<affiliation wicri:level="2"><nlm:affiliation>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Aylward, Philip E" sort="Aylward, Philip E" uniqKey="Aylward P" first="Philip E" last="Aylward">Philip E. Aylward</name>
<affiliation wicri:level="1"><nlm:affiliation>South Australian Health and Medical Research Institute, Flinders University Medical Centre, Adelaide, South Australia, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>South Australian Health and Medical Research Institute, Flinders University Medical Centre, Adelaide, South Australia</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Bonaca, Marc P" sort="Bonaca, Marc P" uniqKey="Bonaca M" first="Marc P" last="Bonaca">Marc P. Bonaca</name>
<affiliation wicri:level="2"><nlm:affiliation>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Budaj, Andrzej" sort="Budaj, Andrzej" uniqKey="Budaj A" first="Andrzej" last="Budaj">Andrzej Budaj</name>
<affiliation wicri:level="1"><nlm:affiliation>Postgraduate Medical School, Grochowski Hospital, Warsaw, Poland.</nlm:affiliation>
<country xml:lang="fr">Pologne</country>
<wicri:regionArea>Postgraduate Medical School, Grochowski Hospital, Warsaw</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Davies, Richard Y" sort="Davies, Richard Y" uniqKey="Davies R" first="Richard Y" last="Davies">Richard Y. Davies</name>
<affiliation wicri:level="2"><nlm:affiliation>Metabolic Pathways and Cardiovascular Unit, Research and Development, GlaxoSmithKline, Collegeville, Pennsylvania.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Metabolic Pathways and Cardiovascular Unit, Research and Development, GlaxoSmithKline, Collegeville</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Dellborg, Mikael" sort="Dellborg, Mikael" uniqKey="Dellborg M" first="Mikael" last="Dellborg">Mikael Dellborg</name>
<affiliation wicri:level="1"><nlm:affiliation>Sahlgrenska University Hospital/Ostra and Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Sahlgrenska University Hospital/Ostra and Sahlgrenska Academy, University of Gothenburg, Gothenburg</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Fox, Keith A A" sort="Fox, Keith A A" uniqKey="Fox K" first="Keith A A" last="Fox">Keith A A. Fox</name>
<affiliation wicri:level="2"><nlm:affiliation>Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, Scotland.</nlm:affiliation>
<country>Royaume-Uni</country>
<placeName><region type="country">Écosse</region>
</placeName>
<wicri:cityArea>Centre for Cardiovascular Science, University of Edinburgh, Edinburgh</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Gutierrez, Jorge Antonio T" sort="Gutierrez, Jorge Antonio T" uniqKey="Gutierrez J" first="Jorge Antonio T" last="Gutierrez">Jorge Antonio T. Gutierrez</name>
<affiliation wicri:level="2"><nlm:affiliation>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Hamm, Christian" sort="Hamm, Christian" uniqKey="Hamm C" first="Christian" last="Hamm">Christian Hamm</name>
<affiliation wicri:level="1"><nlm:affiliation>Kerckhoff Heart Center, Bad Nauheim, University of Giessen, Giessen, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Kerckhoff Heart Center, Bad Nauheim, University of Giessen, Giessen</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kiss, Robert G" sort="Kiss, Robert G" uniqKey="Kiss R" first="Robert G" last="Kiss">Robert G. Kiss</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Cardiology, Military Hospital, Budapest, Hungary.</nlm:affiliation>
<country xml:lang="fr">Hongrie</country>
<wicri:regionArea>Department of Cardiology, Military Hospital, Budapest</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kovar, Frantisek" sort="Kovar, Frantisek" uniqKey="Kovar F" first="František" last="Kovar">František Kovar</name>
<affiliation><nlm:affiliation>Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic.</nlm:affiliation>
<wicri:noCountry code="subField">Slovak Republic</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Kuder, Julia F" sort="Kuder, Julia F" uniqKey="Kuder J" first="Julia F" last="Kuder">Julia F. Kuder</name>
<affiliation wicri:level="2"><nlm:affiliation>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Im, Kyung Ah" sort="Im, Kyung Ah" uniqKey="Im K" first="Kyung Ah" last="Im">Kyung Ah Im</name>
<affiliation wicri:level="2"><nlm:affiliation>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Lepore, John J" sort="Lepore, John J" uniqKey="Lepore J" first="John J" last="Lepore">John J. Lepore</name>
<affiliation wicri:level="2"><nlm:affiliation>Metabolic Pathways and Cardiovascular Unit, Research and Development, GlaxoSmithKline, Collegeville, Pennsylvania.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Metabolic Pathways and Cardiovascular Unit, Research and Development, GlaxoSmithKline, Collegeville</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Lopez Sendon, Jose L" sort="Lopez Sendon, Jose L" uniqKey="Lopez Sendon J" first="Jose L" last="Lopez-Sendon">Jose L. Lopez-Sendon</name>
<affiliation wicri:level="1"><nlm:affiliation>Cardiovascular Division, University Hospital La Paz, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Cardiovascular Division, University Hospital La Paz, Madrid</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ophuis, Ton Oude" sort="Ophuis, Ton Oude" uniqKey="Ophuis T" first="Ton Oude" last="Ophuis">Ton Oude Ophuis</name>
<affiliation wicri:level="1"><nlm:affiliation>Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands.</nlm:affiliation>
<country xml:lang="fr" wicri:curation="lc">Pays-Bas</country>
<wicri:regionArea>Canisius-Wilhelmina Hospital, Nijmegen</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Parkhomenko, Alexandr" sort="Parkhomenko, Alexandr" uniqKey="Parkhomenko A" first="Alexandr" last="Parkhomenko">Alexandr Parkhomenko</name>
<affiliation wicri:level="1"><nlm:affiliation>Ukranian Strazhesko Institute of Cardiology, Kiev, Ukraine.</nlm:affiliation>
<country xml:lang="fr">Ukraine</country>
<wicri:regionArea>Ukranian Strazhesko Institute of Cardiology, Kiev</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Shannon, Jennifer B" sort="Shannon, Jennifer B" uniqKey="Shannon J" first="Jennifer B" last="Shannon">Jennifer B. Shannon</name>
<affiliation wicri:level="2"><nlm:affiliation>PAREXEL International, Durham, North Carolina.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
<wicri:cityArea>PAREXEL International, Durham</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Spinar, Jindrich" sort="Spinar, Jindrich" uniqKey="Spinar J" first="Jindrich" last="Spinar">Jindrich Spinar</name>
<affiliation wicri:level="1"><nlm:affiliation>University Hospital, Jihlavska, Brno, Czech Republic.</nlm:affiliation>
<country xml:lang="fr">République tchèque</country>
<wicri:regionArea>University Hospital, Jihlavska, Brno</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Tanguay, Jean Francois" sort="Tanguay, Jean Francois" uniqKey="Tanguay J" first="Jean-Francois" last="Tanguay">Jean-Francois Tanguay</name>
<affiliation wicri:level="1"><nlm:affiliation>Montreal Heart Institute and University of Montreal, Montreal, Quebec, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Montreal Heart Institute and University of Montreal, Montreal, Quebec</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ruda, Mikhail" sort="Ruda, Mikhail" uniqKey="Ruda M" first="Mikhail" last="Ruda">Mikhail Ruda</name>
<affiliation wicri:level="1"><nlm:affiliation>Cardiology Research Center, Moscow, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Cardiology Research Center, Moscow</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Steg, P Gabriel" sort="Steg, P Gabriel" uniqKey="Steg P" first="P Gabriel" last="Steg">P Gabriel Steg</name>
<affiliation wicri:level="1"><nlm:affiliation>Département Hospitalo-Universitaire FIRE, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, and Université Paris-Diderot, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Département Hospitalo-Universitaire FIRE, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, and Université Paris-Diderot, Paris</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Theroux, Pierre" sort="Theroux, Pierre" uniqKey="Theroux P" first="Pierre" last="Theroux">Pierre Theroux</name>
<affiliation wicri:level="1"><nlm:affiliation>Montreal Heart Institute and University of Montreal, Montreal, Quebec, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Montreal Heart Institute and University of Montreal, Montreal, Quebec</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wiviott, Stephen D" sort="Wiviott, Stephen D" uniqKey="Wiviott S" first="Stephen D" last="Wiviott">Stephen D. Wiviott</name>
<affiliation wicri:level="2"><nlm:affiliation>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Laws, Ian" sort="Laws, Ian" uniqKey="Laws I" first="Ian" last="Laws">Ian Laws</name>
<affiliation wicri:level="2"><nlm:affiliation>Metabolic Pathways and Cardiovascular Unit, Research and Development, GlaxoSmithKline, Collegeville, Pennsylvania.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Metabolic Pathways and Cardiovascular Unit, Research and Development, GlaxoSmithKline, Collegeville</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Sabatine, Marc S" sort="Sabatine, Marc S" uniqKey="Sabatine M" first="Marc S" last="Sabatine">Marc S. Sabatine</name>
<affiliation wicri:level="2"><nlm:affiliation>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Morrow, David A" sort="Morrow, David A" uniqKey="Morrow D" first="David A" last="Morrow">David A. Morrow</name>
<affiliation wicri:level="2"><nlm:affiliation>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston</wicri:cityArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:27043082</idno>
<idno type="pmid">27043082</idno>
<idno type="doi">10.1001/jama.2016.3609</idno>
<idno type="wicri:Area/PubMed/Corpus">001F87</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001F87</idno>
<idno type="wicri:Area/PubMed/Curation">001F62</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001F62</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial.</title>
<author><name sortKey="O Donoghue, Michelle L" sort="O Donoghue, Michelle L" uniqKey="O Donoghue M" first="Michelle L" last="O'Donoghue">Michelle L. O'Donoghue</name>
<affiliation wicri:level="2"><nlm:affiliation>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Glaser, Ruchira" sort="Glaser, Ruchira" uniqKey="Glaser R" first="Ruchira" last="Glaser">Ruchira Glaser</name>
<affiliation wicri:level="2"><nlm:affiliation>Metabolic Pathways and Cardiovascular Unit, Research and Development, GlaxoSmithKline, Collegeville, Pennsylvania.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Metabolic Pathways and Cardiovascular Unit, Research and Development, GlaxoSmithKline, Collegeville</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Cavender, Matthew A" sort="Cavender, Matthew A" uniqKey="Cavender M" first="Matthew A" last="Cavender">Matthew A. Cavender</name>
<affiliation wicri:level="2"><nlm:affiliation>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Aylward, Philip E" sort="Aylward, Philip E" uniqKey="Aylward P" first="Philip E" last="Aylward">Philip E. Aylward</name>
<affiliation wicri:level="1"><nlm:affiliation>South Australian Health and Medical Research Institute, Flinders University Medical Centre, Adelaide, South Australia, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>South Australian Health and Medical Research Institute, Flinders University Medical Centre, Adelaide, South Australia</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Bonaca, Marc P" sort="Bonaca, Marc P" uniqKey="Bonaca M" first="Marc P" last="Bonaca">Marc P. Bonaca</name>
<affiliation wicri:level="2"><nlm:affiliation>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Budaj, Andrzej" sort="Budaj, Andrzej" uniqKey="Budaj A" first="Andrzej" last="Budaj">Andrzej Budaj</name>
<affiliation wicri:level="1"><nlm:affiliation>Postgraduate Medical School, Grochowski Hospital, Warsaw, Poland.</nlm:affiliation>
<country xml:lang="fr">Pologne</country>
<wicri:regionArea>Postgraduate Medical School, Grochowski Hospital, Warsaw</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Davies, Richard Y" sort="Davies, Richard Y" uniqKey="Davies R" first="Richard Y" last="Davies">Richard Y. Davies</name>
<affiliation wicri:level="2"><nlm:affiliation>Metabolic Pathways and Cardiovascular Unit, Research and Development, GlaxoSmithKline, Collegeville, Pennsylvania.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Metabolic Pathways and Cardiovascular Unit, Research and Development, GlaxoSmithKline, Collegeville</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Dellborg, Mikael" sort="Dellborg, Mikael" uniqKey="Dellborg M" first="Mikael" last="Dellborg">Mikael Dellborg</name>
<affiliation wicri:level="1"><nlm:affiliation>Sahlgrenska University Hospital/Ostra and Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Sahlgrenska University Hospital/Ostra and Sahlgrenska Academy, University of Gothenburg, Gothenburg</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Fox, Keith A A" sort="Fox, Keith A A" uniqKey="Fox K" first="Keith A A" last="Fox">Keith A A. Fox</name>
<affiliation wicri:level="2"><nlm:affiliation>Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, Scotland.</nlm:affiliation>
<country>Royaume-Uni</country>
<placeName><region type="country">Écosse</region>
</placeName>
<wicri:cityArea>Centre for Cardiovascular Science, University of Edinburgh, Edinburgh</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Gutierrez, Jorge Antonio T" sort="Gutierrez, Jorge Antonio T" uniqKey="Gutierrez J" first="Jorge Antonio T" last="Gutierrez">Jorge Antonio T. Gutierrez</name>
<affiliation wicri:level="2"><nlm:affiliation>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Hamm, Christian" sort="Hamm, Christian" uniqKey="Hamm C" first="Christian" last="Hamm">Christian Hamm</name>
<affiliation wicri:level="1"><nlm:affiliation>Kerckhoff Heart Center, Bad Nauheim, University of Giessen, Giessen, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Kerckhoff Heart Center, Bad Nauheim, University of Giessen, Giessen</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kiss, Robert G" sort="Kiss, Robert G" uniqKey="Kiss R" first="Robert G" last="Kiss">Robert G. Kiss</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Cardiology, Military Hospital, Budapest, Hungary.</nlm:affiliation>
<country xml:lang="fr">Hongrie</country>
<wicri:regionArea>Department of Cardiology, Military Hospital, Budapest</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kovar, Frantisek" sort="Kovar, Frantisek" uniqKey="Kovar F" first="František" last="Kovar">František Kovar</name>
<affiliation><nlm:affiliation>Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic.</nlm:affiliation>
<wicri:noCountry code="subField">Slovak Republic</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Kuder, Julia F" sort="Kuder, Julia F" uniqKey="Kuder J" first="Julia F" last="Kuder">Julia F. Kuder</name>
<affiliation wicri:level="2"><nlm:affiliation>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Im, Kyung Ah" sort="Im, Kyung Ah" uniqKey="Im K" first="Kyung Ah" last="Im">Kyung Ah Im</name>
<affiliation wicri:level="2"><nlm:affiliation>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Lepore, John J" sort="Lepore, John J" uniqKey="Lepore J" first="John J" last="Lepore">John J. Lepore</name>
<affiliation wicri:level="2"><nlm:affiliation>Metabolic Pathways and Cardiovascular Unit, Research and Development, GlaxoSmithKline, Collegeville, Pennsylvania.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Metabolic Pathways and Cardiovascular Unit, Research and Development, GlaxoSmithKline, Collegeville</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Lopez Sendon, Jose L" sort="Lopez Sendon, Jose L" uniqKey="Lopez Sendon J" first="Jose L" last="Lopez-Sendon">Jose L. Lopez-Sendon</name>
<affiliation wicri:level="1"><nlm:affiliation>Cardiovascular Division, University Hospital La Paz, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Cardiovascular Division, University Hospital La Paz, Madrid</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ophuis, Ton Oude" sort="Ophuis, Ton Oude" uniqKey="Ophuis T" first="Ton Oude" last="Ophuis">Ton Oude Ophuis</name>
<affiliation wicri:level="1"><nlm:affiliation>Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands.</nlm:affiliation>
<country xml:lang="fr" wicri:curation="lc">Pays-Bas</country>
<wicri:regionArea>Canisius-Wilhelmina Hospital, Nijmegen</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Parkhomenko, Alexandr" sort="Parkhomenko, Alexandr" uniqKey="Parkhomenko A" first="Alexandr" last="Parkhomenko">Alexandr Parkhomenko</name>
<affiliation wicri:level="1"><nlm:affiliation>Ukranian Strazhesko Institute of Cardiology, Kiev, Ukraine.</nlm:affiliation>
<country xml:lang="fr">Ukraine</country>
<wicri:regionArea>Ukranian Strazhesko Institute of Cardiology, Kiev</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Shannon, Jennifer B" sort="Shannon, Jennifer B" uniqKey="Shannon J" first="Jennifer B" last="Shannon">Jennifer B. Shannon</name>
<affiliation wicri:level="2"><nlm:affiliation>PAREXEL International, Durham, North Carolina.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
<wicri:cityArea>PAREXEL International, Durham</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Spinar, Jindrich" sort="Spinar, Jindrich" uniqKey="Spinar J" first="Jindrich" last="Spinar">Jindrich Spinar</name>
<affiliation wicri:level="1"><nlm:affiliation>University Hospital, Jihlavska, Brno, Czech Republic.</nlm:affiliation>
<country xml:lang="fr">République tchèque</country>
<wicri:regionArea>University Hospital, Jihlavska, Brno</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Tanguay, Jean Francois" sort="Tanguay, Jean Francois" uniqKey="Tanguay J" first="Jean-Francois" last="Tanguay">Jean-Francois Tanguay</name>
<affiliation wicri:level="1"><nlm:affiliation>Montreal Heart Institute and University of Montreal, Montreal, Quebec, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Montreal Heart Institute and University of Montreal, Montreal, Quebec</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ruda, Mikhail" sort="Ruda, Mikhail" uniqKey="Ruda M" first="Mikhail" last="Ruda">Mikhail Ruda</name>
<affiliation wicri:level="1"><nlm:affiliation>Cardiology Research Center, Moscow, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Cardiology Research Center, Moscow</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Steg, P Gabriel" sort="Steg, P Gabriel" uniqKey="Steg P" first="P Gabriel" last="Steg">P Gabriel Steg</name>
<affiliation wicri:level="1"><nlm:affiliation>Département Hospitalo-Universitaire FIRE, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, and Université Paris-Diderot, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Département Hospitalo-Universitaire FIRE, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, and Université Paris-Diderot, Paris</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Theroux, Pierre" sort="Theroux, Pierre" uniqKey="Theroux P" first="Pierre" last="Theroux">Pierre Theroux</name>
<affiliation wicri:level="1"><nlm:affiliation>Montreal Heart Institute and University of Montreal, Montreal, Quebec, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Montreal Heart Institute and University of Montreal, Montreal, Quebec</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wiviott, Stephen D" sort="Wiviott, Stephen D" uniqKey="Wiviott S" first="Stephen D" last="Wiviott">Stephen D. Wiviott</name>
<affiliation wicri:level="2"><nlm:affiliation>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Laws, Ian" sort="Laws, Ian" uniqKey="Laws I" first="Ian" last="Laws">Ian Laws</name>
<affiliation wicri:level="2"><nlm:affiliation>Metabolic Pathways and Cardiovascular Unit, Research and Development, GlaxoSmithKline, Collegeville, Pennsylvania.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Metabolic Pathways and Cardiovascular Unit, Research and Development, GlaxoSmithKline, Collegeville</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Sabatine, Marc S" sort="Sabatine, Marc S" uniqKey="Sabatine M" first="Marc S" last="Sabatine">Marc S. Sabatine</name>
<affiliation wicri:level="2"><nlm:affiliation>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Morrow, David A" sort="Morrow, David A" uniqKey="Morrow D" first="David A" last="Morrow">David A. Morrow</name>
<affiliation wicri:level="2"><nlm:affiliation>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston</wicri:cityArea>
</affiliation>
</author>
</analytic>
<series><title level="j">JAMA</title>
<idno type="eISSN">1538-3598</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Algorithms</term>
<term>C-Reactive Protein (analysis)</term>
<term>Cyclopropanes (adverse effects)</term>
<term>Cyclopropanes (therapeutic use)</term>
<term>Double-Blind Method</term>
<term>Drug Administration Schedule</term>
<term>Female</term>
<term>Hospitalization</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Myocardial Infarction (drug therapy)</term>
<term>Myocardial Infarction (enzymology)</term>
<term>Myocardial Infarction (mortality)</term>
<term>Myocardial Ischemia (prevention & control)</term>
<term>Myocardial Ischemia (surgery)</term>
<term>Myocardial Revascularization</term>
<term>Protein Kinase Inhibitors (adverse effects)</term>
<term>Protein Kinase Inhibitors (therapeutic use)</term>
<term>Pyridines (adverse effects)</term>
<term>Pyridines (therapeutic use)</term>
<term>Recurrence</term>
<term>Secondary Prevention</term>
<term>Treatment Failure</term>
<term>p38 Mitogen-Activated Protein Kinases (antagonists & inhibitors)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Algorithmes</term>
<term>Calendrier d'administration des médicaments</term>
<term>Cyclopropanes (effets indésirables)</term>
<term>Cyclopropanes (usage thérapeutique)</term>
<term>Femelle</term>
<term>Hospitalisation</term>
<term>Humains</term>
<term>Infarctus du myocarde (enzymologie)</term>
<term>Infarctus du myocarde (mortalité)</term>
<term>Infarctus du myocarde (traitement médicamenteux)</term>
<term>Inhibiteurs de protéines kinases (effets indésirables)</term>
<term>Inhibiteurs de protéines kinases (usage thérapeutique)</term>
<term>Ischémie myocardique ()</term>
<term>Mâle</term>
<term>Méthode en double aveugle</term>
<term>Protéine C-réactive (analyse)</term>
<term>Prévention secondaire</term>
<term>Pyridines (effets indésirables)</term>
<term>Pyridines (usage thérapeutique)</term>
<term>Revascularisation myocardique</term>
<term>Récidive</term>
<term>Sujet âgé</term>
<term>p38 Mitogen-Activated Protein Kinases (antagonistes et inhibiteurs)</term>
<term>Échec thérapeutique</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Cyclopropanes</term>
<term>Protein Kinase Inhibitors</term>
<term>Pyridines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>C-Reactive Protein</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>p38 Mitogen-Activated Protein Kinases</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Cyclopropanes</term>
<term>Protein Kinase Inhibitors</term>
<term>Pyridines</term>
</keywords>
<keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Protéine C-réactive</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>p38 Mitogen-Activated Protein Kinases</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Myocardial Infarction</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Cyclopropanes</term>
<term>Inhibiteurs de protéines kinases</term>
<term>Pyridines</term>
</keywords>
<keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>Infarctus du myocarde</term>
</keywords>
<keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>Myocardial Infarction</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Myocardial Infarction</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Infarctus du myocarde</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Myocardial Ischemia</term>
</keywords>
<keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Myocardial Ischemia</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infarctus du myocarde</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Cyclopropanes</term>
<term>Inhibiteurs de protéines kinases</term>
<term>Pyridines</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Algorithms</term>
<term>Double-Blind Method</term>
<term>Drug Administration Schedule</term>
<term>Female</term>
<term>Hospitalization</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Myocardial Revascularization</term>
<term>Recurrence</term>
<term>Secondary Prevention</term>
<term>Treatment Failure</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Algorithmes</term>
<term>Calendrier d'administration des médicaments</term>
<term>Femelle</term>
<term>Hospitalisation</term>
<term>Humains</term>
<term>Ischémie myocardique</term>
<term>Mâle</term>
<term>Méthode en double aveugle</term>
<term>Prévention secondaire</term>
<term>Revascularisation myocardique</term>
<term>Récidive</term>
<term>Sujet âgé</term>
<term>Échec thérapeutique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">p38 Mitogen-activated protein kinase (MAPK)-stimulated inflammation is implicated in atherogenesis, plaque destabilization, and maladaptive processes in myocardial infarction (MI). Pilot data in a phase 2 trial in non-ST elevation MI indicated that the p38 MAPK inhibitor losmapimod attenuates inflammation and may improve outcomes.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27043082</PMID>
<DateCreated><Year>2016</Year>
<Month>04</Month>
<Day>20</Day>
</DateCreated>
<DateCompleted><Year>2016</Year>
<Month>05</Month>
<Day>01</Day>
</DateCompleted>
<DateRevised><Year>2016</Year>
<Month>10</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>315</Volume>
<Issue>15</Issue>
<PubDate><Year>2016</Year>
<Month>Apr</Month>
<Day>19</Day>
</PubDate>
</JournalIssue>
<Title>JAMA</Title>
<ISOAbbreviation>JAMA</ISOAbbreviation>
</Journal>
<ArticleTitle>Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial.</ArticleTitle>
<Pagination><MedlinePgn>1591-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2016.3609</ELocationID>
<Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">p38 Mitogen-activated protein kinase (MAPK)-stimulated inflammation is implicated in atherogenesis, plaque destabilization, and maladaptive processes in myocardial infarction (MI). Pilot data in a phase 2 trial in non-ST elevation MI indicated that the p38 MAPK inhibitor losmapimod attenuates inflammation and may improve outcomes.</AbstractText>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the efficacy and safety of losmapimod on cardiovascular outcomes in patients hospitalized with an acute myocardial infarction.</AbstractText>
<AbstractText Label="DESIGN, SETTING, AND PATIENTS" NlmCategory="METHODS">LATITUDE-TIMI 60, a randomized, placebo-controlled, double-blind, parallel-group trial conducted at 322 sites in 34 countries from June 3, 2014, until December 8, 2015. Part A consisted of a leading cohort (n = 3503) to provide an initial assessment of safety and exploratory efficacy before considering progression to part B (approximately 22,000 patients). Patients were considered potentially eligible for enrollment if they had been hospitalized with an acute MI and had at least 1 additional predictor of cardiovascular risk.</AbstractText>
<AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Patients were randomized to either twice-daily losmapimod (7.5 mg; n = 1738) or matching placebo (n = 1765) on a background of guideline-recommended therapy. Patients were treated for 12 weeks and followed up for an additional 12 weeks.</AbstractText>
<AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">The primary end point was the composite of cardiovascular death, MI, or severe recurrent ischemia requiring urgent coronary revascularization with the principal analysis specified at week 12.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">In part A, among the 3503 patients randomized (median age, 66 years; 1036 [29.6%] were women), 99.1% had complete ascertainment for the primary outcome. The primary end point occurred by 12 weeks in 123 patients treated with placebo (7.0%) and 139 patients treated with losmapimod (8.1%; hazard ratio, 1.16; 95% CI, 0.91-1.47; P = .24). The on-treatment rates of serious adverse events were 16.0% with losmapimod and 14.2% with placebo.</AbstractText>
<AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Among patients with acute MI, use of losmapimod compared with placebo did not reduce the risk of major ischemic cardiovascular events. The results of this exploratory efficacy study did not justify proceeding to a larger efficacy trial in the existing patient population.</AbstractText>
<AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">clinicaltrials.gov Identifier: NCT02145468.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>O'Donoghue</LastName>
<ForeName>Michelle L</ForeName>
<Initials>ML</Initials>
<AffiliationInfo><Affiliation>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Glaser</LastName>
<ForeName>Ruchira</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Metabolic Pathways and Cardiovascular Unit, Research and Development, GlaxoSmithKline, Collegeville, Pennsylvania.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cavender</LastName>
<ForeName>Matthew A</ForeName>
<Initials>MA</Initials>
<AffiliationInfo><Affiliation>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Aylward</LastName>
<ForeName>Philip E</ForeName>
<Initials>PE</Initials>
<AffiliationInfo><Affiliation>South Australian Health and Medical Research Institute, Flinders University Medical Centre, Adelaide, South Australia, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bonaca</LastName>
<ForeName>Marc P</ForeName>
<Initials>MP</Initials>
<AffiliationInfo><Affiliation>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Budaj</LastName>
<ForeName>Andrzej</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Postgraduate Medical School, Grochowski Hospital, Warsaw, Poland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Davies</LastName>
<ForeName>Richard Y</ForeName>
<Initials>RY</Initials>
<AffiliationInfo><Affiliation>Metabolic Pathways and Cardiovascular Unit, Research and Development, GlaxoSmithKline, Collegeville, Pennsylvania.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dellborg</LastName>
<ForeName>Mikael</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Sahlgrenska University Hospital/Ostra and Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Fox</LastName>
<ForeName>Keith A A</ForeName>
<Initials>KA</Initials>
<AffiliationInfo><Affiliation>Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, Scotland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gutierrez</LastName>
<ForeName>Jorge Antonio T</ForeName>
<Initials>JA</Initials>
<AffiliationInfo><Affiliation>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hamm</LastName>
<ForeName>Christian</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Kerckhoff Heart Center, Bad Nauheim, University of Giessen, Giessen, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kiss</LastName>
<ForeName>Robert G</ForeName>
<Initials>RG</Initials>
<AffiliationInfo><Affiliation>Department of Cardiology, Military Hospital, Budapest, Hungary.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kovar</LastName>
<ForeName>František</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kuder</LastName>
<ForeName>Julia F</ForeName>
<Initials>JF</Initials>
<AffiliationInfo><Affiliation>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Im</LastName>
<ForeName>Kyung Ah</ForeName>
<Initials>KA</Initials>
<AffiliationInfo><Affiliation>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lepore</LastName>
<ForeName>John J</ForeName>
<Initials>JJ</Initials>
<AffiliationInfo><Affiliation>Metabolic Pathways and Cardiovascular Unit, Research and Development, GlaxoSmithKline, Collegeville, Pennsylvania.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lopez-Sendon</LastName>
<ForeName>Jose L</ForeName>
<Initials>JL</Initials>
<AffiliationInfo><Affiliation>Cardiovascular Division, University Hospital La Paz, Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ophuis</LastName>
<ForeName>Ton Oude</ForeName>
<Initials>TO</Initials>
<AffiliationInfo><Affiliation>Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Parkhomenko</LastName>
<ForeName>Alexandr</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Ukranian Strazhesko Institute of Cardiology, Kiev, Ukraine.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Shannon</LastName>
<ForeName>Jennifer B</ForeName>
<Initials>JB</Initials>
<AffiliationInfo><Affiliation>PAREXEL International, Durham, North Carolina.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Spinar</LastName>
<ForeName>Jindrich</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>University Hospital, Jihlavska, Brno, Czech Republic.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tanguay</LastName>
<ForeName>Jean-Francois</ForeName>
<Initials>JF</Initials>
<AffiliationInfo><Affiliation>Montreal Heart Institute and University of Montreal, Montreal, Quebec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ruda</LastName>
<ForeName>Mikhail</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Cardiology Research Center, Moscow, Russia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Steg</LastName>
<ForeName>P Gabriel</ForeName>
<Initials>PG</Initials>
<AffiliationInfo><Affiliation>Département Hospitalo-Universitaire FIRE, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, and Université Paris-Diderot, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Theroux</LastName>
<ForeName>Pierre</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Montreal Heart Institute and University of Montreal, Montreal, Quebec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wiviott</LastName>
<ForeName>Stephen D</ForeName>
<Initials>SD</Initials>
<AffiliationInfo><Affiliation>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Laws</LastName>
<ForeName>Ian</ForeName>
<Initials>I</Initials>
<AffiliationInfo><Affiliation>Metabolic Pathways and Cardiovascular Unit, Research and Development, GlaxoSmithKline, Collegeville, Pennsylvania.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sabatine</LastName>
<ForeName>Marc S</ForeName>
<Initials>MS</Initials>
<AffiliationInfo><Affiliation>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Morrow</LastName>
<ForeName>David A</ForeName>
<Initials>DA</Initials>
<AffiliationInfo><Affiliation>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><CollectiveName>LATITUDE-TIMI 60 Investigators</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName>
<AccessionNumberList><AccessionNumber>NCT02145468</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>JAMA</MedlineTA>
<NlmUniqueID>7501160</NlmUniqueID>
<ISSNLinking>0098-7484</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C543534">6-(5-((cyclopropylamino)carbonyl)-3-fluoro-2-methylphenyl)-N-(2,2-dimethylprpyl)-3-pyridinecarboxamide</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D003521">Cyclopropanes</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>9007-41-4</RegistryNumber>
<NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D048051">p38 Mitogen-Activated Protein Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Thorac Dis. 2016 Sep;8(9):2328-2330</RefSource>
<PMID Version="1">27746967</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn"><RefSource>J Thorac Dis. 2016 Sep;8(9):E1047-E1049</RefSource>
<PMID Version="1">27747059</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn"><RefSource>J Thorac Dis. 2016 Sep;8(9):E1068-E1071</RefSource>
<PMID Version="1">27747066</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName>
<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003521" MajorTopicYN="N">Cyclopropanes</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017202" MajorTopicYN="N">Myocardial Ischemia</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
<QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009204" MajorTopicYN="N">Myocardial Revascularization</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055502" MajorTopicYN="N">Secondary Prevention</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D048051" MajorTopicYN="N">p38 Mitogen-Activated Protein Kinases</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName>
</MeshHeading>
</MeshHeadingList>
<InvestigatorList><Investigator ValidYN="Y"><LastName>Ardissino</LastName>
<ForeName>Diego</ForeName>
<Initials>D</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Atar</LastName>
<ForeName>Dan</ForeName>
<Initials>D</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Budaj</LastName>
<ForeName>Andrzej</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Corbalán</LastName>
<ForeName>Ramón</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Dalby</LastName>
<ForeName>Anthony J</ForeName>
<Initials>AJ</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Dellborg</LastName>
<ForeName>Mikael</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Diaz</LastName>
<ForeName>Rafael</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Dorobantu</LastName>
<ForeName>Maria</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Goudev</LastName>
<ForeName>Assen R</ForeName>
<Initials>AR</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Hamm</LastName>
<ForeName>Christian</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Huo</LastName>
<ForeName>Yong</ForeName>
<Initials>Y</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Kiss</LastName>
<ForeName>Robert</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Kovar</LastName>
<ForeName>Frantisek</ForeName>
<Initials>F</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Lewis</LastName>
<ForeName>Basil</ForeName>
<Initials>B</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Merlini</LastName>
<ForeName>Piera</ForeName>
<Initials>P</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Nicolau</LastName>
<ForeName>José C</ForeName>
<Initials>JC</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Ophuis</LastName>
<ForeName>Ton Oude</ForeName>
<Initials>TO</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Parkhomenko</LastName>
<ForeName>Alexander</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Ruda</LastName>
<ForeName>Mikhail</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Seung</LastName>
<ForeName>Ki-Bae</ForeName>
<Initials>KB</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Sinnaeve</LastName>
<ForeName>Peter</ForeName>
<Initials>P</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Jensen</LastName>
<ForeName>Jan Skov</ForeName>
<Initials>JS</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Ŝpinar</LastName>
<ForeName>Jindřich</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Sritara</LastName>
<ForeName>Piyamitr</ForeName>
<Initials>P</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Tanguay</LastName>
<ForeName>Jean-François</ForeName>
<Initials>JF</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Tziakas</LastName>
<ForeName>Dimitiros</ForeName>
<Initials>D</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Uren</LastName>
<ForeName>Neal</ForeName>
<Initials>N</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>White</LastName>
<ForeName>Harvey</ForeName>
<Initials>H</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>O'Donoghue</LastName>
<ForeName>Michelle</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Alves de Lima</LastName>
<ForeName>Alberto</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Gomez Vilamajo</LastName>
<ForeName>Oscar</ForeName>
<Initials>O</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Hrabar</LastName>
<ForeName>Adrian</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Licheri</LastName>
<ForeName>Alberto</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Macin</LastName>
<ForeName>Stella</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Zapata</LastName>
<ForeName>Gerardo</ForeName>
<Initials>G</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Amerena</LastName>
<ForeName>John</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Hammett</LastName>
<ForeName>Christopher</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Lehman</LastName>
<ForeName>Sam</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Muhlmann</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Nguyen</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Poulter</LastName>
<ForeName>Rohan</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Raffel</LastName>
<ForeName>Christopher</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Roberts-Thomson</LastName>
<ForeName>Philip</ForeName>
<Initials>P</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Stramer</LastName>
<ForeName>Gregory</ForeName>
<Initials>G</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Van Gaal</LastName>
<ForeName>William</ForeName>
<Initials>W</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Charlier</LastName>
<ForeName>Filip</ForeName>
<Initials>F</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Cools</LastName>
<ForeName>Frank</ForeName>
<Initials>F</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Dangoisse</LastName>
<ForeName>Vincent</ForeName>
<Initials>V</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>De Raedt</LastName>
<ForeName>Herbert</ForeName>
<Initials>H</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Hermans</LastName>
<ForeName>Kurt</ForeName>
<Initials>K</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Hoffer</LastName>
<ForeName>Etienne</ForeName>
<Initials>E</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Missault</LastName>
<ForeName>Luc</ForeName>
<Initials>L</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Sinnaeve</LastName>
<ForeName>Peter</ForeName>
<Initials>P</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Verhaert</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Vervoort</LastName>
<ForeName>Geert</ForeName>
<Initials>G</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Atzev</LastName>
<ForeName>Borislav</ForeName>
<Initials>B</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Draganov</LastName>
<ForeName>Todor</ForeName>
<Initials>T</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Gelev</LastName>
<ForeName>Valeri</ForeName>
<Initials>V</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Goudev</LastName>
<ForeName>Assen</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Lazov</LastName>
<ForeName>Petar</ForeName>
<Initials>P</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Mihov</LastName>
<ForeName>Atanas</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Petrov</LastName>
<ForeName>Ivo</ForeName>
<Initials>I</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Billingsley</LastName>
<ForeName>Ian</ForeName>
<Initials>I</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Cheung</LastName>
<ForeName>Stephen</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Costa Vitali</LastName>
<ForeName>Atilio</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Della Siega</LastName>
<ForeName>Anthony</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Kassam</LastName>
<ForeName>Saleem</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Nguyen</LastName>
<ForeName>Michel</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Pearce</LastName>
<ForeName>Murray</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Tanguay</LastName>
<ForeName>Jean-Francois</ForeName>
<Initials>JF</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Wong</LastName>
<ForeName>Graham</ForeName>
<Initials>G</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Pérez Pino</LastName>
<ForeName>Luis</ForeName>
<Initials>L</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Pincetti</LastName>
<ForeName>Christian</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Rodriguez Venegas</LastName>
<ForeName>Manuel</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Verdejo</LastName>
<ForeName>Hugo</ForeName>
<Initials>H</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Coufal</LastName>
<ForeName>Zdenek</ForeName>
<Initials>Z</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Gregor</LastName>
<ForeName>Pavel</ForeName>
<Initials>P</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Homza</LastName>
<ForeName>Miroslav</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Horak</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Matejka</LastName>
<ForeName>Jan</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Sedlon</LastName>
<ForeName>Pavel</ForeName>
<Initials>P</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Smid</LastName>
<ForeName>Ondrej</ForeName>
<Initials>O</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Spacek</LastName>
<ForeName>Radim</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Spinar</LastName>
<ForeName>Jindrich</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Stasek</LastName>
<ForeName>Josef</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Tousek</LastName>
<ForeName>Frantisek</ForeName>
<Initials>F</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Brønnum-Schou</LastName>
<ForeName>Jens</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Nielsen</LastName>
<ForeName>Henrik</ForeName>
<Initials>H</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Rasmussen</LastName>
<ForeName>Soeren Lind</ForeName>
<Initials>SL</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Skov Jensen</LastName>
<ForeName>Jan</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Hedman</LastName>
<ForeName>Anu</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Reinmets</LastName>
<ForeName>Julia</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Soopold</LastName>
<ForeName>Ullar</ForeName>
<Initials>U</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Agraou</LastName>
<ForeName>Benaissa</ForeName>
<Initials>B</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Cottin</LastName>
<ForeName>Yves</ForeName>
<Initials>Y</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>De Labriolle</LastName>
<ForeName>Axel</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Decoulx</LastName>
<ForeName>Eric</ForeName>
<Initials>E</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Delarche</LastName>
<ForeName>Nicolas</ForeName>
<Initials>N</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Elbaz</LastName>
<ForeName>Meyer</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Ohlmann</LastName>
<ForeName>Patrick</ForeName>
<Initials>P</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Probst</LastName>
<ForeName>Vincent</ForeName>
<Initials>V</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Schiele</LastName>
<ForeName>François</ForeName>
<Initials>F</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Steg</LastName>
<ForeName>Gabriel</ForeName>
<Initials>G</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Appel</LastName>
<ForeName>Karl-Friedrich</ForeName>
<Initials>KF</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Bavendiek</LastName>
<ForeName>Udo</ForeName>
<Initials>U</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Butter</LastName>
<ForeName>Christian</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Fuisting</LastName>
<ForeName>Jan</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Ghanem</LastName>
<ForeName>Alexander</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Groenefeld</LastName>
<ForeName>Gerian</ForeName>
<Initials>G</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Hamm</LastName>
<ForeName>Christian</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Hoffman</LastName>
<ForeName>Ursula</ForeName>
<Initials>U</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Kadel</LastName>
<ForeName>Christoph</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Karakas</LastName>
<ForeName>Mahir</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Leschke</LastName>
<ForeName>Matthias</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Mangner</LastName>
<ForeName>Norman</ForeName>
<Initials>N</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Moellmann</LastName>
<ForeName>Helge</ForeName>
<Initials>H</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Olbrich</LastName>
<ForeName>Hans-Georg</ForeName>
<Initials>HG</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Reith</LastName>
<ForeName>Sebastian</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Schwimmbeck</LastName>
<ForeName>Peter</ForeName>
<Initials>P</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Sechtem</LastName>
<ForeName>Udo</ForeName>
<Initials>U</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Smettan</LastName>
<ForeName>Jan</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Stellbrink</LastName>
<ForeName>Christoph</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>vom Dahl</LastName>
<ForeName>Juergen</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Vorpahl</LastName>
<ForeName>Marc</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Werner</LastName>
<ForeName>Nikos</ForeName>
<Initials>N</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Zeh</LastName>
<ForeName>Wolfgang</ForeName>
<Initials>W</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Zirlik</LastName>
<ForeName>Andreas</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Kanakakis</LastName>
<ForeName>Ioannis</ForeName>
<Initials>I</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Kyriakides</LastName>
<ForeName>Zenon</ForeName>
<Initials>Z</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Mantas</LastName>
<ForeName>Ioannis</ForeName>
<Initials>I</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Styliadis</LastName>
<ForeName>Ioannis</ForeName>
<Initials>I</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Tziakas</LastName>
<ForeName>Dimitrios</ForeName>
<Initials>D</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Zarifis</LastName>
<ForeName>Ioannis</ForeName>
<Initials>I</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Chan</LastName>
<ForeName>Kwok Keung</ForeName>
<Initials>KK</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Wong</LastName>
<ForeName>Chi Yuen</ForeName>
<Initials>CY</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Yan</LastName>
<ForeName>Ping Yen Bryan</ForeName>
<Initials>PY</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Benczúr</LastName>
<ForeName>Béla</ForeName>
<Initials>B</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Faluközy</LastName>
<ForeName>József</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Kiss</LastName>
<ForeName>Róbert Gábor</ForeName>
<Initials>RG</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Lupkovics</LastName>
<ForeName>Géza</ForeName>
<Initials>G</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Merkely</LastName>
<ForeName>Béla</ForeName>
<Initials>B</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Atar</LastName>
<ForeName>Shaul</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Banai</LastName>
<ForeName>Shmuel</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Katz</LastName>
<ForeName>Amos</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Meisel</LastName>
<ForeName>Simcha</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Mosseri</LastName>
<ForeName>Morris</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Ardissino</LastName>
<ForeName>Diego</ForeName>
<Initials>D</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Cavallini</LastName>
<ForeName>Claudio</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Maria De Biase</LastName>
<ForeName>Anna</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Morocutti</LastName>
<ForeName>Giorgio</ForeName>
<Initials>G</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Musumeci</LastName>
<ForeName>Giuseppe</ForeName>
<Initials>G</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Pirelli</LastName>
<ForeName>Salvatore</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Salvioni</LastName>
<ForeName>Alessandro</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Hong</LastName>
<ForeName>Bum Kee</ForeName>
<Initials>BK</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Jeong</LastName>
<ForeName>Jin-Ok</ForeName>
<Initials>JO</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Jeong</LastName>
<ForeName>MyungHo</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Kim</LastName>
<ForeName>Chong-Jin</ForeName>
<Initials>CJ</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Kim</LastName>
<ForeName>Hyo-Soo</ForeName>
<Initials>HS</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Rha</LastName>
<ForeName>SeungWoon</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Seung</LastName>
<ForeName>Ki-Bae</ForeName>
<Initials>KB</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Yoon</LastName>
<ForeName>Junghan</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Carrillo-Calvillo</LastName>
<ForeName>Jorge</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Esturau-Santalo</LastName>
<ForeName>Ramon-Miguel</ForeName>
<Initials>RM</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Dirksen</LastName>
<ForeName>Maurits</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Gosselink</LastName>
<ForeName>Antonius</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Hamer</LastName>
<ForeName>Barnabas J B</ForeName>
<Initials>BJ</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Magro</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Nierop</LastName>
<ForeName>Pieter</ForeName>
<Initials>P</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Oude Ophuis</LastName>
</Investigator>
<Investigator ValidYN="Y"><LastName>Perik</LastName>
<ForeName>Patrick J</ForeName>
<Initials>PJ</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Prins</LastName>
<ForeName>Fransisco J</ForeName>
<Initials>FJ</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Rensing</LastName>
<ForeName>Bernard J W M</ForeName>
<Initials>BJ</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Ronner</LastName>
<ForeName>Eelko</ForeName>
<Initials>E</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Slagboom</LastName>
<ForeName>Ton</ForeName>
<Initials>T</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Troquay</LastName>
<ForeName>Roland</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>van Daele</LastName>
<ForeName>Marcus</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>van der Heijden</LastName>
<ForeName>Robert</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Devlin</LastName>
<ForeName>Gerard</ForeName>
<Initials>G</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Elliott</LastName>
<ForeName>John</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Harding</LastName>
<ForeName>Scott</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Scott</LastName>
<ForeName>Douglas</ForeName>
<Initials>D</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Stewart</LastName>
<ForeName>Ralph</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Ternouth</LastName>
<ForeName>Ian</ForeName>
<Initials>I</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Atar</LastName>
<ForeName>Dan</ForeName>
<Initials>D</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Høgalmen</LastName>
<ForeName>Geir</ForeName>
<Initials>G</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Hysing</LastName>
<ForeName>Jan</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Larsen</LastName>
<ForeName>Alf</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Trovik</LastName>
<ForeName>Thor</ForeName>
<Initials>T</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Añonuevo</LastName>
<ForeName>John</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Hay</LastName>
<ForeName>Eduardo Tin</ForeName>
<Initials>ET</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Marañon</LastName>
<ForeName>Donato</ForeName>
<Initials>D</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Miranda</LastName>
<ForeName>Ariel</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Bujaj</LastName>
<ForeName>Andrzej</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Gessek</LastName>
<ForeName>Jacek</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Jaworska</LastName>
<ForeName>Krystyna</ForeName>
<Initials>K</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Kubica</LastName>
<ForeName>Jacek</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Miekus</LastName>
<ForeName>Pawel</ForeName>
<Initials>P</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Mysiak</LastName>
<ForeName>Andrzej</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Przewlocki</LastName>
<ForeName>Tadeusz</ForeName>
<Initials>T</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Raczak</LastName>
<ForeName>Grzegorz</ForeName>
<Initials>G</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Serafin</LastName>
<ForeName>Ryszard</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Trebacz</LastName>
<ForeName>Jaroslaw</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Tyllo</LastName>
<ForeName>Mateusz</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Wlodarczak</LastName>
<ForeName>Adrian</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Wojcik</LastName>
<ForeName>Jaroslaw</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Cinteza</LastName>
<ForeName>Mircea</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Dorobantu</LastName>
<ForeName>Maria</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Musetescu</LastName>
<ForeName>Rodica</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Aksentyev</LastName>
<ForeName>Sergey</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Apartsin</LastName>
<ForeName>Konstantin</ForeName>
<Initials>K</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Barbarash</LastName>
<ForeName>Olga</ForeName>
<Initials>O</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Berns</LastName>
<ForeName>Svetlana</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Bessonova</LastName>
<ForeName>Nina</ForeName>
<Initials>N</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Duda</LastName>
<ForeName>Alexey</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Duplyakov</LastName>
<ForeName>Dmitry</ForeName>
<Initials>D</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Ermoshkina</LastName>
<ForeName>Lyudmila</ForeName>
<Initials>L</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Gordeev</LastName>
<ForeName>Ivan</ForeName>
<Initials>I</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Kobalava</LastName>
<ForeName>Zhanna</ForeName>
<Initials>Z</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Kostenko</LastName>
<ForeName>Victor</ForeName>
<Initials>V</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Lapin</LastName>
<ForeName>Oleg</ForeName>
<Initials>O</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Markov</LastName>
<ForeName>Valentin</ForeName>
<Initials>V</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Orlikova</LastName>
<ForeName>Olga</ForeName>
<Initials>O</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Rebrov</LastName>
<ForeName>Andrey</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Ruda</LastName>
<ForeName>Mikhail</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Shalaev</LastName>
<ForeName>Sergey</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Tsyba</LastName>
<ForeName>Larisa</ForeName>
<Initials>L</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Vishnevsky</LastName>
<ForeName>Alexander</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Yakushin</LastName>
<ForeName>Sergey</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Hranai</LastName>
<ForeName>Marian</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Hricak</LastName>
<ForeName>Vasil</ForeName>
<Initials>V</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Juhas</LastName>
<ForeName>Stanislav</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Kovar</LastName>
<ForeName>Frantisek</ForeName>
<Initials>F</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Abelson</LastName>
<ForeName>Mark</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Basson</LastName>
<ForeName>Matthys</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Cyster</LastName>
<ForeName>H P</ForeName>
<Initials>HP</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Dalby</LastName>
<ForeName>Anthony</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Dawood</LastName>
<ForeName>Saleem</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Horak</LastName>
<ForeName>Adrian</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Saaiman</LastName>
<ForeName>Jan</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Barrabes Riu</LastName>
<ForeName>José Antonio</ForeName>
<Initials>JA</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Cequier Fillat</LastName>
<ForeName>Angel</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Delia</LastName>
<ForeName>Manuel Almendro</ForeName>
<Initials>MA</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Fernández-Avilés Díaz</LastName>
<ForeName>Francisco</ForeName>
<Initials>F</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Genover</LastName>
<ForeName>Xavier Bosch</ForeName>
<Initials>XB</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>González Juanatey</LastName>
<ForeName>José Ramón</ForeName>
<Initials>JR</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Lekuona Goya</LastName>
<ForeName>Iñaki</ForeName>
<Initials>I</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>López de Sa</LastName>
<ForeName>Esteban</ForeName>
<Initials>E</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Macaya</LastName>
<ForeName>Carlos</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Navarro</LastName>
<ForeName>Manuel Jiménez</ForeName>
<Initials>MJ</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Ortega Marcos</LastName>
<ForeName>Javier</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Zamorano</LastName>
<ForeName>José Luis</ForeName>
<Initials>JL</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Bandh</LastName>
<ForeName>Stellan</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Boberg</LastName>
<ForeName>Gunnar</ForeName>
<Initials>G</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Christensen</LastName>
<ForeName>Kjeld</ForeName>
<Initials>K</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Holmgren</LastName>
<ForeName>Christina</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Hornestam</LastName>
<ForeName>Björn</ForeName>
<Initials>B</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Mooe</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Råmunddal</LastName>
<ForeName>Truls</ForeName>
<Initials>T</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Wagner</LastName>
<ForeName>Henrik</ForeName>
<Initials>H</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Chiang</LastName>
<ForeName>Chern-En</ForeName>
<Initials>CE</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Hou</LastName>
<ForeName>Jia-Yin</ForeName>
<Initials>JY</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Hsia</LastName>
<ForeName>Chien-Hsun</ForeName>
<Initials>CH</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Huang</LastName>
<ForeName>Wei-Chun</ForeName>
<Initials>WC</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Ji-Hung</ForeName>
<Initials>JH</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Chotinaiwattarakul</LastName>
</Investigator>
<Investigator ValidYN="Y"><LastName>Suithichaiyakul</LastName>
<ForeName>Taworn</ForeName>
<Initials>T</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Yamwong</LastName>
<ForeName>Sukit</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Chunhakasem</LastName>
</Investigator>
<Investigator ValidYN="Y"><LastName>Kuanprasert</LastName>
<ForeName>Srun</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Kraiz</LastName>
<ForeName>Igor</ForeName>
<Initials>I</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Malynovsky</LastName>
<ForeName>Yaroslav</ForeName>
<Initials>Y</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Parkhomenko</LastName>
<ForeName>Oleksandr</ForeName>
<Initials>O</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Pavlyk</LastName>
<ForeName>Stepan</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Rishko</LastName>
<ForeName>Mykola</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Vakaliuk</LastName>
<ForeName>Igor</ForeName>
<Initials>I</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Zhurba</LastName>
<ForeName>Svitlana</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Glover</LastName>
<ForeName>Jason</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Irving</LastName>
<ForeName>Robert</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Levy</LastName>
<ForeName>Terry</ForeName>
<Initials>T</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Purcell</LastName>
<ForeName>Ian</ForeName>
<Initials>I</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Pye</LastName>
<ForeName>Maurice</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Uren</LastName>
<ForeName>Neal</ForeName>
<Initials>N</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Albirini</LastName>
<ForeName>Abdulhay</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Aycock</LastName>
<ForeName>George</ForeName>
<Initials>G</Initials>
<Suffix>Jr</Suffix>
</Investigator>
<Investigator ValidYN="Y"><LastName>Bach</LastName>
<ForeName>Richard</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Banerjee</LastName>
<ForeName>Subhash</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Barr</LastName>
<ForeName>Lawrence</ForeName>
<Initials>L</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Bernstein</LastName>
<ForeName>Marc</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Brechtken</LastName>
<ForeName>Johannes</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Burchenal</LastName>
<ForeName>Joseph</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Burke</LastName>
<ForeName>Martin</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Chan</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Chandler</LastName>
<ForeName>Bleakley</ForeName>
<Initials>B</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Chandna</LastName>
<ForeName>Harish</ForeName>
<Initials>H</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Chane</LastName>
<ForeName>Majed</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Conn</LastName>
<ForeName>Eric</ForeName>
<Initials>E</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Dodds</LastName>
<ForeName>Al</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Duffy</LastName>
<ForeName>Brendan</ForeName>
<Initials>B</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Eaton</LastName>
<ForeName>Gregory</ForeName>
<Initials>G</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Ferrier</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>French</LastName>
<ForeName>William</ForeName>
<Initials>W</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Gammon</LastName>
<ForeName>Roger</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Gessler</LastName>
<ForeName>Carl</ForeName>
<Initials>C</Initials>
<Suffix>Jr</Suffix>
</Investigator>
<Investigator ValidYN="Y"><LastName>Ginete</LastName>
<ForeName>Wilson</ForeName>
<Initials>W</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Graham</LastName>
<ForeName>Bruce</ForeName>
<Initials>B</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Gray</LastName>
<ForeName>Richard</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Gruberg</LastName>
<ForeName>Luis</ForeName>
<Initials>L</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Guidera</LastName>
<ForeName>Steven</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Henderson</LastName>
<ForeName>David A</ForeName>
<Initials>DA</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Hill</LastName>
<ForeName>Roger</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Hoang</LastName>
<ForeName>Kheit</ForeName>
<Initials>K</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Jackson</LastName>
<ForeName>Charles</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Jaffrani</LastName>
<ForeName>Naseem</ForeName>
<Initials>N</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Katopodis</LastName>
<ForeName>John</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Kavanaugh</LastName>
<ForeName>Kevin</ForeName>
<Initials>K</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Kazziha</LastName>
<ForeName>Samer</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Klugherz</LastName>
<ForeName>Bruce</ForeName>
<Initials>B</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Kraft</LastName>
<ForeName>Philip</ForeName>
<Initials>P</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Laddu</LastName>
<ForeName>Abhay</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Lambert</LastName>
<ForeName>Charles</ForeName>
<Initials>C</Initials>
<Suffix>Jr</Suffix>
</Investigator>
<Investigator ValidYN="Y"><LastName>Larrain</LastName>
<ForeName>German</ForeName>
<Initials>G</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Lee</LastName>
<ForeName>Kwan</ForeName>
<Initials>K</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Lotun</LastName>
<ForeName>Kapildeo</ForeName>
<Initials>K</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Loussararain</LastName>
<ForeName>Arthur</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Mansouri</LastName>
<ForeName>Vafa</ForeName>
<Initials>V</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>McCullum</LastName>
<ForeName>Kevin</ForeName>
<Initials>K</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>McLaurin</LastName>
<ForeName>Brent</ForeName>
<Initials>B</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Mulkay</LastName>
<ForeName>Angel</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Nahhas</LastName>
<ForeName>Geiorg</ForeName>
<Initials>G</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Othman</LastName>
<ForeName>Islam</ForeName>
<Initials>I</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Pap</LastName>
<ForeName>John</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Pasquini</LastName>
<ForeName>John</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Perlman</LastName>
<ForeName>Richard</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Prashad</LastName>
<ForeName>Rakesh</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Rao</LastName>
<ForeName>Vijay</ForeName>
<Initials>V</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Rosenberg</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Ruff</LastName>
<ForeName>Christian</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Sane</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Secaira</LastName>
<ForeName>Roberto</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Sharma</LastName>
<ForeName>Sanjiv</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Siegel</LastName>
<ForeName>Craig</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Stuckey</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Tahirkheli</LastName>
<ForeName>Naeem</ForeName>
<Initials>N</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Tang</LastName>
<ForeName>Aylmer</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Uretsky</LastName>
<ForeName>Barry</ForeName>
<Initials>B</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Warden</LastName>
<ForeName>Bradford</ForeName>
<Initials>B</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Webber</LastName>
<ForeName>Jeffrey</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Weiss</LastName>
<ForeName>Robert</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Wickemeyer</LastName>
<ForeName>William</ForeName>
<Initials>W</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Zahr</LastName>
<ForeName>Firas</ForeName>
<Initials>F</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Zenni</LastName>
<ForeName>Martin</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Zidar</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
</Investigator>
</InvestigatorList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>4</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>4</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>5</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">27043082</ArticleId>
<ArticleId IdType="pii">2511223</ArticleId>
<ArticleId IdType="doi">10.1001/jama.2016.3609</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F62 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001F62 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:27043082
   |texte=   Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:27043082" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial.

Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Curation

No country items

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki